Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Statement of preliminary issues for GlaxoSmithKline

Reissued media release - correction to earlier release on GSK/ Novartis statement of preliminary issues Correction: This media release replaces and corrects the release issued earlier today on GlaxoSmithKline’s application to acquire Novartis’ consumer healthcare business, which contained an error in the first paragraph. The application is not a joint application and was lodged by GlaxoSmithKline.

Issued 17 October 2014

Release No. 40

Statement of preliminary issues for GlaxoSmithKline’s application to acquire Novartis’ consumer healthcare business

The Commerce Commission has published a statement of preliminary issues relating to an application for GlaxoSmithKline to acquire Novartis’ consumer healthcare business.

The statement outlines the key competition issues that the Commission currently considers will be important in deciding whether or not to grant clearance.

The Commission invites submissions from parties who consider that they have information relevant to the Commission’s consideration of this matter. Submissions can be sent to the registrar@comcom.govt.nz with the reference GSK/Novartis in the subject line of your email or to PO Box 2351, Wellington 6140 by close of business Thursday 30 October 2014.

You can find the Statement of Preliminary Issues and the public version of the application on the Commission’s website:

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

http://www.comcom.govt.nz/business-competition/mergers-and-acquisitions/clearances/clearances-register/

Background

GSK is an international healthcare company active in over 150 countries worldwide. GSK’s principal areas of operation are in the development, manufacture and sale of pharmaceutical, vaccine, and consumer healthcare products. In New Zealand, GSK operates consumer healthcare and prescription pharmaceutical divisions.

Novartis is a global group of healthcare companies active in a range of areas including pharmaceuticals, eye care, animal health, vaccines and consumer health. In New Zealand, Novartis has a marketing, sales and distribution operation for its pharmaceutical and animal health products. Novartis’ consumer healthcare operation in New Zealand is operated from Australia.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.